Aude Desnoyer
Villejuif, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.
Journal: European urology
Published: March 24, 2025
High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 26, 2024
How to decrease bone marrow collection volume and risk contaminations via the operating room cell concentration?
Journal: Bone marrow transplantation
Published: December 29, 2023
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Journal: Journal for immunotherapy of cancer
Published: April 23, 2022
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.
Journal: Journal for immunotherapy of cancer
Published: December 19, 2021
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.
Journal: Cancers
Published: November 01, 2020
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer.
Journal: Translational lung cancer research
Published: July 10, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 15, 2020
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 10, 2019
Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 10, 2019
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 10, 2019
Last Updated: 09/26/2026